Methods of using RAD51 inhibitors for treatment of pancreatic cancer
US-12064419-B2 · Aug 20, 2024 · US
US9517230B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9517230-B2 |
| Application number | US-201514744205-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 19, 2015 |
| Priority date | Jan 26, 2011 |
| Publication date | Dec 13, 2016 |
| Grant date | Dec 13, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease.
Opening claim text (preview).
What is claimed is: 1. A method of treating, reducing, or inhibiting a bacterial infection in a subject, comprising administering to the subject an effective amount of an RNase inhibitor of the following structure: or a pharmaceutically acceptable salt or prodrug thereof, wherein the bacterial infection is a Staphylococcus infection. 2. The method of claim 1 , wherein the Staphylococcus infection is a Staphylococcus aureus infection. 3. The method of claim 2 , wherein the Staphylococcus aureus infection is a drug-resistant Staphylococcus aureus infection. 4. The method of claim 2 , wherein the Staphylococcus aureus infection is a biofilm-associated Staphylococcus aureus infection. 5. The method of claim 1 , wherein the RNase inhibitor is a RnpA inhibitor. 6. The method of claim 1 , further comprising administering a second compound, wherein the second compound is an antibacterial compound. 7. A method of inhibiting a bacterial ribonuclease comprising contacting the bacterial ribonuclease with an effective amount of an RNase inhibitor of the following structure: or a pharmaceutically acceptable salt or prodrug thereof, wherein the bacterial ribonuclease is Staphylococcus aureus RNase P. 8. The method of claim 7 , wherein the bacterial ribonuclease is RnpA. 9. The method of claim 7 , wherein the contacting occurs in vivo. 10. The method of claim 7 , wherein the contacting occurs in vitro.
not condensed and containing further heterocyclic rings · CPC title
Ribonucleases (RNAses); Deoxyribonucleases (DNAses) · CPC title
involving esterase · CPC title
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.